Sabatolimab With or Without Spartalizumab in Advanced Solid Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Clin. Cancer Res 2021 Apr 21;[EPub Ahead of Print], G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, J Sarantopoulos, PL Bedard, CC Lin, FS Hodi, S Wilgenhof, A Santoro, CA Sabatos-Peyton, TA Longmire, A Xyrafas, H Sun, S Gutzwiller, L Manenti, A NaingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.